Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Åsa Romé, Ulf Persson, Charlotte Ekdahl & Gunvor Gard. (2009) Physical activity on prescription (PAP): Costs and consequences of a randomized, controlled trial in primary healthcare. Scandinavian Journal of Primary Health Care 27:4, pages 216-222.
Read now
Read now
Thomas Hedner, Sverre E. Kjeldsen & Krzysztof Narkiewicz. (2005) Health economy of the metabolic syndrome pandemic. Blood Pressure 14:3, pages 131-132.
Read now
Read now
Lena Sandström & Agneta Ståhle. (2005) Rehabilitation of elderly with coronary heart disease – Improvement in quality of life at a low cost. Advances in Physiotherapy 7:2, pages 60-66.
Read now
Read now
Jonas Tovi, Anna-Karin Furhoff, Per Lennerhagen & Peter Engfeldt. (1997) Starting insulin therapy in elderly non-insulin-dependent diabetic patients at a health care centre. Methodological and economic aspects. Scandinavian Journal of Primary Health Care 15:2, pages 87-91.
Read now
Read now
B. Jonsson, C. Christiansen, O. Johnell, J. Hedbrandt & G. Karlsson. (1996) Cost-effectiveness of Fracture Prevention in Established Osteoporosis. Scandinavian Journal of Rheumatology 25:sup103, pages 30-38.
Read now
Read now
M. Johannesson, L. Borgquist, P. Nilsson-Ehle, B. Jönsson, T. Ekbom & L. Lindholm. (1993) The cost of screening for hypercholesterolaemia– results from a clinical trial in Swedish primary health care. Scandinavian Journal of Clinical and Laboratory Investigation 53:7, pages 725-732.
Read now
Read now
Articles from other publishers (24)
Richard Ssegonja, Filipa Sampaio, Iman Alaie, Anna Philipson, Lars Hagberg, Krahn Murray, Anna Sarkadi, Sophie Langenskiöld, Ulf Jonsson & Inna Feldman. (2020) Cost-effectiveness of an indicated preventive intervention for depression in adolescents: a model to support decision making. Journal of Affective Disorders 277, pages 789-799.
Crossref
Crossref
A. Truedsson, K. Hjalte, B. Sunzel & G. Warfvinge. (2013) Maxillary sinus augmentation with iliac autograft - a health-economic analysis. Clinical Oral Implants Research 24:10, pages 1088-1093.
Crossref
Crossref
Adrian R. Levy, Alison M. Davie, Nicole C. Brazier, Farah Jivraj, Lorne E. Albrecht, David Gratton & Charles W. Lynde. (2012) Economic burden of moderate to severe plaque psoriasis in Canada. International Journal of Dermatology 51:12, pages 1432-1440.
Crossref
Crossref
Sue Jowett, Stirling Bryan, Isabelle Mahé, David Brieger, Jonas Carlsson, Bernt Kartman & Mark Nevinson. (2008) A Multinational Investigation of Time and Traveling Costs in Attending Anticoagulation Clinics. Value in Health 11:2, pages 207-212.
Crossref
Crossref
J Juan, R Estiarte, E Colomé, M Artés, F.J Jiménez & J Alonso. (2003) Burden of illness of Crohn’s disease in Spain. Digestive and Liver Disease 35:12, pages 853-861.
Crossref
Crossref
B. Jonsson, L. Hansson & N.-O. Stalhammar. (2003) Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine 253:4, pages 472-480.
Crossref
Crossref
Helios Pardell, Ricard Tresserras, Pedro Armario & Raquel Hern??ndez del Rey. (2000) Pharmacoeconomic Considerations in the Management of Hypertension. Drugs 59:Supplement 2, pages 13-20.
Crossref
Crossref
J. Mar, R. Pastor & R. Abásolo. (1999) Análisis de costes de la monitorización ambulatoria de la presión arterial en hipertensión leve. Gaceta Sanitaria 13:5, pages 384-390.
Crossref
Crossref
Suzuki. (1998) Treatment of benign prostatic hyperplasia and hypertension in elderly hypertensive patients. British Journal of Urology 81:S1, pages 51-55.
Crossref
Crossref
Magnus Johannesson, David Meltzer & Richard M. O'Conor. (2016) Incorporating Future Costs in Medical Cost-Effectiveness Analysis. Medical Decision Making 17:4, pages 382-389.
Crossref
Crossref
G. J. Hankey. (2008) The effect of treating people with reversible ischaemic attacks of the brain and eye on the incidence of stroke in Australia. Australian and New Zealand Journal of Medicine 27:4, pages 420-430.
Crossref
Crossref
JL Pool. (1996) DOXAZOSIN: A NEW APPROACH TO HYPERTENSION AND BENIGN PROSTATIC HYPERPLASIA. International Journal of Clinical Practice 50:3, pages 154-163.
Crossref
Crossref
Magnus JohannessonMagnus Johannesson. 1996. Theory and Methods of Economic Evaluation of Health Care. Theory and Methods of Economic Evaluation of Health Care
101
125
.
MATS RIBACKE. (2009) Treatment preferences, return visit planning and factors affecting hypertension practice amongst general practitioners and internal medicine specialists (The General Practitioner Hypertension Practice Study). Journal of Internal Medicine 237:5, pages 473-478.
Crossref
Crossref
B. Jönsson, C. Christiansen, O. Johnell & J. Hedbrandt. (1995) Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporosis International 5:2, pages 136-142.
Crossref
Crossref
M. JOHANNESSON, S. AGEWALL, M. HARTFORD, T. HEDNER & B. FAGERBERG. (2009) The cost‐effectiveness of a cardiovascular multiple‐risk‐factor intervention programme in treated hypertensive men. Journal of Internal Medicine 237:1, pages 19-26.
Crossref
Crossref
Y. TOMSON, M. JOHANNESSON & H. ÅBERG. (2009) The costs and effects of two different lipid intervention programmes in primary health care. Journal of Internal Medicine 237:1, pages 13-17.
Crossref
Crossref
Magnus Johannesson. (2016) The Impact of Age on the Cost - Effectiveness of Hypertension Treatment. Medical Decision Making 14:3, pages 236-244.
Crossref
Crossref
Magnus Johannesson. (1994) The cost-effectiveness of the switch towards more expensive antihypertensive drugs. Health Policy 28:1, pages 1-13.
Crossref
Crossref
M. JOHANNESSON, B. DAHLÖF, L. H. LINDHOLM, T. EKBOM, L. HANSSON, A. ODÉN, B. SCHERSTÉN, P.‐O. WESTER & B. JÖNSSON. (2009) The cost‐effectiveness of treating hypertension in elderly people—an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). Journal of Internal Medicine 234:3, pages 317-323.
Crossref
Crossref
P. NILSSON, D. K. G. ANDERSSON, P.‐E. ANDERSSON, Å SCHWAN, B. ÖSTLIND, R. MALMBORG, H. LITHELL & O. K. ANDERSSON. (2009) Cardiovascular risk factors in treated hypertensives—a nation‐wide, cross‐sectional study in Sweden. Journal of Internal Medicine 233:3, pages 239-245.
Crossref
Crossref
Magnus Johannesson. (2009) Economic Evaluation of Hypertension Treatment. International Journal of Technology Assessment in Health Care 8:3, pages 506-523.
Crossref
Crossref
M. JOHANNESSON, H. Åberg, L. AGRÉUS, L. BORGQUIST & B. Jönsson. (2009) Cost‐benefit analysis of non‐pharmacological treatment of hypertension. Journal of Internal Medicine 230:4, pages 307-312.
Crossref
Crossref
Magnus Johannesson & Bengt Jönsson. (1991) Cost-effectiveness analysis of hypertension treatment — A review of methodological issues. Health Policy 19:1, pages 55-77.
Crossref
Crossref